Test different doses of cancer drugs with ezabenlimab
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that cannot be removed by surgery, or it has spread, and it has been confirmed by a biopsy or scan test
- Your cancer must have at least one measurable spot the trial can track, and you must be able to provide two tumor biopsies (before treatment and during treatment)
- You are age 18 or older, and you sign informed consent (you can still join without agreeing to extra optional tissue storage/biobanking)
- Your body health/lab tests must be strong enough (blood counts, kidney function, liver tests) for safe study treatment
- You should be well enough to do daily activities (ECOG score 0 or 1)
- You must not have had certain recent cancer treatments, some prior immune drug exposures, or immune-related lung problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.